Business Lead/Manager

Job Title

Business Lead/Manager

Expected Salary and Benefits

$55k – 80k per year, commensurate with experience

Benefits: Employee Stock Option Plan, 401(k)-matching, Dental Insurance, Health
Insurance, Paid Time Off

Job Type

Full-time

Job Description

Position Details:

A Business Lead or Manager position is available immediately at Inimmune Corp, an exciting Biotech company working on the discovery and development of novel immunotherapies for the treatment of allergies, infectious disease and cancer. This is an excellent opportunity to join a world-class multidisciplinary research and development team that is well funded and has strong connections in both academia and industry. We are looking for highly motivated candidates with strong organizational, communication and accounting skills. A scientific background or scientific related experience would be a plus but is not required. This position is expected to be a full-time appointment with the responsibilities and compensation being dependent upon the qualifications/experience of the candidate.

Basic Qualifications: A Bachelors degree (BA or BS) in business or accounting with at
least 3 years of accounting/financial experience and a CPA would be a plus. Scientific
background is a plus, but not required.

Preferred Qualifications:

The appointee should be self-motivated and eager to provide general administrative and business support across all functional areas at Inimmune (Management, Project Teams, HR, Legal, Accounting). Depth and complexity of assigned tasks will vary based on experience and are likely to adapt with the role. These tasks may include managing company invoices, accounts, large purchases, business aspects of contracts/grants, timekeeping/payroll, updating budgets and forecasting for management/BOD, training others in business related tasks and presenting/communicating business information to the company.

Preferred Skills and Experience:

Demonstrated experience and/or knowledge in the following techniques:

  • Self-motivated, detail oriented individual with strong organizational skills
  • Strong administrative editing, typing, and formatting skills with experience assembling large technical reports or documents
  • Ability to synthesize large quantities of complex financial data into actionable information
  • Ability to work and effectively communicate with senior-level management
  • Knowledge of financial reporting
  • Strong demonstrated use of Excel, Word, PowerPoint and Quickbooks
  • Depth of experience with spreadsheets, ability to comfortably and proficiently use formulas and worksheets in Excel
  • Excellent verbal and written communication skills
  • Ability to maintain confidential corporate and technical information
  • Ability to perform multiple tasks at once and prioritize work based on supervisor feedback
  • Quickly learn and apply new skills appropriate to completing administrative tasks
  • Ability and willingness to undertake collaborative work, gather information from external sources as necessary and provide appropriate feedback to others
  • Setup timelines and budgets with project management input and track them effectively

Responsibilities For Business Manager:

  • Monitor and administer the day-to-day financial operations within the company (payroll, benefits, invoicing, spending, and other transactions)
  • Prepare monthly and quarterly management reporting
  • Work with management in preparing budgets and periodic forecasts
  • Evaluate and make appropriate improvements to accounting processes ensuring that practices are efficient, effective, and support the overall goals of the organization
  • Participate in strategic data analysis, research, and modeling for senior company leadership
  • Support project analysis, validation of plans, and ad-hoc requests
  • Manage the company’s financial accounting, monitoring, and reporting systems
  • Ensure compliance with accounting policies and regulatory requirements
  • Provide purchasing support for employees
  • Coordinate with third party accounting firm in tracking labor, cost reporting, invoice generation, and expense monitoring

About Inimmune

Inimmune was formed in 2016 by an experienced team of biotech/pharmaceutical industry professionals. This team of chemists, immunologists and formulation scientists have been at the cutting edge of innovation for over 20 years and are now working to create new immunotherapies directed at making meaningful and lasting clinical impacts in the areas of allergy, autoimmunity, infectious disease and cancer. Through its technology, assets, and expertise, Inimmune is poised to become an industry leader in the fields of immunotherapy, infectious disease and immuno-oncology. Inimmune is headquartered in beautiful Missoula, Montana, A culturally vibrant community of about 70,000, surrounded by mountain grandeur which was recently ranked in the “top 20 best college towns with a population of less than 250,000” by the American Institute for Economic Research and ranked 9th in Outside Magazine’s “The 16 Greatest Places to Live in America” in 2014. Many national publications recognize Missoula for its high quality of life. Abundant recreational opportunities in surrounding state and national forests and nearby Glacier National Park and Yellowstone National Park complement a thriving intellectual atmosphere.

To learn more about Inimmune, please visit our website at www.Inimmune.com

How to Apply

Priority Application Date: November 15, 2021

Please submit the following application materials:

  • Letter of Interest – addressing the stated required skills for the position and motivation to join Inimmune
  • Detailed resume listing education and describing work experience
  • Names and contact information for three (3) professional references

Our goal at Inimmune is to recruit, hire, and maintain a diverse workforce. Equal employment opportunity is good business. It is also the law. Equal opportunity applies to all aspects of employment, including recruitment, selection, hiring, training, transfer, promotion, termination, compensation, and benefits. As an equal opportunity employer, Inimmune does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. Furthermore, Inimmune will make reasonable accommodations for qualified individuals with known disabilities unless doing so would result in an undue hardship or a substantial safety health risk.

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics.

Contact

© Copyright 2022 Inimmune. All Rights Reserved.

Website Design by Digital Marketing Missoula
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.

TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING